Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $33M seed (Mar 2026). Owkin Dx spinout. Multimodal oncology AI analyzing pathology images + clinical data for treatment decisions. Positioned against Tempus and Foundation Medicine.
Waiv is a digital pathology AI company spun out of Owkin's diagnostic unit in March 2026 with a $33 million seed round, inheriting Owkin's proven multimodal oncology AI stack that has been validated in multiple peer-reviewed publications and clinical collaborations with major academic medical centers. The platform analyzes H&E-stained pathology slide images combined with genomic, clinical, and outcomes data to extract prognostic and predictive biomarkers that help oncologists select optimal treatments for individual cancer patients.
Raised $900M Series E at $11B valuation (Oct 2025). CEO projects ~$2B in 2026 sales. Launched women's health LLM (Feb 2026). Team USA LA28 Olympic partner.
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E financing at an $11 billion valuation in October 2025, reflecting the doubling of its revenue to $500 million in 2024 and a projected $1.5–2 billion in 2026 sales as it expands global distribution into India, UAE, and Latin America.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.